Sarcoma | Topics

Ipilimumab Plus Nivolumab Promising for Patients with Metastatic or Unresectable Angiosarcoma
November 21, 2020

A study presented at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting suggested that ipilimumab (Yervoy) plus nivolumab (Opdivo) for patients with metastatic or unresectable angiosarcoma was well-tolerated.

Phase 3 SEAL Study Meets Primary End Point in Patients with Unresectable Dedifferentiated Liposarcoma
November 03, 2020

The phase 3 SEAL study evaluating single agent, oral selinexor (Xpovio) versus matching placebo in patients with advanced unresectable dedifferentiated liposarcoma met its primary end point of a statistically significant increase in progression-free survival.

Lorvotuzumab Mertansine Well-Tolerated in Children at Adult Recommended Dose
October 23, 2020

However, though the CD56 target was confirmed to be expressed in the tumor types studied, the clinical efficacy of lorvotuzumab mertansine was limited.